FDA Orange Book · active-ingredient family
Chlorothiazide; reserpine
Chlorothiazide; reserpine is approved as 1 brand and 6 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:DIUPRES-250 · NDA 011635
1
Brand (NDA)
6
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| DIUPRES-250×2 | MERCK | NDA 011635 | — | Aug 26, 1987 |
Generic (ANDA) products (6)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CHLOROTHIAZIDE AND RESERPINE | HIKMA | ANDA 088557 | — | Dec 22, 1983 | |
| CHLOROTHIAZIDE AND RESERPINE | HIKMA | ANDA 088365 | — | Dec 22, 1983 | |
| CHLOROTHIAZIDE W/ RESERPINE | WATSON LABS | ANDA 088151 | — | Jun 09, 1983 | |
| CHLOROTHIAZIDE-RESERPINE | PHARMOBEDIENT | ANDA 087744 | — | May 06, 1982 | |
| CHLOROTHIAZIDE-RESERPINE | PHARMOBEDIENT | ANDA 087745 | — | May 06, 1982 | |
| CHLOROTHIAZIDE W/ RESERPINE | WATSON LABS | ANDA 084853 | — | Approved Prior to Jan 1, 1982 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Chlorothiazide; reserpine — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
